Combination therapy using interleukin-2 and tumor necrosis facto

Details Combination therapy using interleukin-2 and tumor necrosis facto Combination therapy using interleukin-2 and tumor necrosis facto

1989-06-26

1992-03-24

Stone, Jacqueline

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

514 2, 514 8, 424 852, A61K 3702, A61K 4505

Patent

active

050987020

ABSTRACT:
Anti-tumor activity in mammals can be augmented by administering to the mammalian host a synergistically effective amount of TNF and IL-2 or of TNF and IFN-.beta., or of TNF, IL-2 and IFN-.beta. in combination. The composition of TNF and IL-2 and/or IFN-.beta. may be prepared in vitro or administered separately to the host. If the TNF and IL-2 are administered sequentially, the TNF must be administered prior to the IL-2 to obtain synergy. The composition is useful for treating such cancers as mastocytoma, melanoma, leukemia, lymphoma, mammary adenocarcinoma, and pharyngeal squamous cell carcinoma.

REFERENCES:
patent: 4863727 (1989-09-01), Zimmerman et al.

Affiliated with

Also associated with

Rating

Combination therapy using interleukin-2 and tumor necrosis facto does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination therapy using interleukin-2 and tumor necrosis facto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy using interleukin-2 and tumor necrosis facto will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2008813